Drug Trial Radar · NCT03215693
X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib
Last checked: Nov 20, 2026Latest source record: Aug 16, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
152
Planned (sponsor's estimate)
Start
Sep 28, 2017
Primary completion
Mar 9, 2020
Study completion Dec 2023
Sponsor
- Lead sponsor
- Betta Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 12, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of the study is to evaluate safety and efficacy of X-396(Ensartinib) capsule in patients with ALK-positive non-small cell lung cancer previously treated with crizotinib.While exploring the relationship between biomarkers and drug efficacy and safety.
Conditions
- Non-Small Cell Lung Cancer
Interventions
X-396 capsuleDrug
225mg once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR) based on independent radiology reviewTime frame: 24 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, China
Beijing Chest Hospital,Capital Medical University
Beijing, China
Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences
Beijing, China
Peking Union College Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.